US Edition
CureDuchenne Ventures Invests in Entos Pharmaceuticals
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
CureDuchenne Ventures Invests in Entos Pharmaceuticals
Entos Pharmaceuticals, an Edmonton, Canada-based biotech company that develops genetic medicines, received an investment from CureDuchenne Ventures. The amount of the deal was not disclosed. The company intends to use the funds to create a muscle-targeting therapeutic to deliver full-length dystrophin for the treatment of Duchenne muscular dystrophy (DMD). Led by CEO John Lewis, Entos […] The post CureDuchenne Ventures Invests in Entos Pharmace…
CureDuchenne Ventures Invests in Entos Pharmaceuticals for Development of a Redosable, Full-Length Dystrophin Gene Therapy
Newport Beach, Calif. and Edmonton, Canada (May 22, 2025) – CureDuchenne Ventures announced an initial $1M investment in Entos Pharmaceuticals Inc (Entos), a biotech company that develops genetic medicines utilizing its non-viral, redosable Fusogenix PLV delivery platform. Entos will use this funding to create a muscle-targeting therapeutic to deliver full-length dystrophin for the treatment of Duchenne muscular dystrophy (DMD). Entos’ Fusogenix…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
